Medicamen Organics Limited — Others, 29-05-2025: Statement of deviation(s) or variation(s) under Reg. 32

Medicamen Organics has announced a board meeting and confirmed that the funds raised through its IPO and preferential issue against convertible share warrants have been utilized exactly as planned for the year ended March 31, 2025. The Audit Committee and Board have reviewed and approved these details, reinforcing the company’s financial discipline and transparency. This assurance provides confidence to shareholders that the capital raised is being managed responsibly and aligns with the company’s strategic objectives.